Burning Pain in Your Feet and Hands, Your Genes May Be Amplifying It.

COMT encodes an enzyme that breaks down catecholamines, the family of stress chemicals that includes dopamine, norepinephrine, and epinephrine. In your brain, these chemicals are critical: they modulate focus, mood, and crucially, pain perception. When catecholamine levels are high, pain signals are amplified through the trigeminal and dorsal horn pain pathways. When they’re low, pain is naturally suppressed. COMT is your brain’s on-off valve for these chemicals.

The Val158Met variant, carried by roughly 25% of people with European ancestry in homozygous slow form, creates a slower-acting enzyme. That means catecholamines linger in your synapses longer than they should. In people with the slow COMT variant, stress chemicals accumulate, and pain signaling is amplified through the trigeminal and central nervous system pathways. The effect is compounded by caffeine, stress, and stimulant medications, all of which raise catecholamine levels further.

If you have a slow COMT variant, you likely notice that stressful days make your burning pain worse. Caffeine intensifies it. Cold, wind, or emotional strain can trigger flare-ups. Your nervous system is exquisitely sensitive to catecholamine shifts because you can’t clear them efficiently. You’re not imagining the connection between stress and pain; it’s built into your genetics.

MTHFR encodes methylenetetrahydrofolate reductase, the enzyme that converts dietary folate into methylfolate, the active form your cells actually use. Methylation is the foundation of countless biological processes: DNA repair, neurotransmitter synthesis, myelin formation, and immune regulation. In the context of pain, MTHFR variants disrupt the methylation cycle, which impairs the production of nitric oxide, a critical signaling molecule that regulates vascular tone and pain perception in nerve tissue.

The C677T variant, present in approximately 40% of people with European ancestry, reduces MTHFR enzyme efficiency by 40 to 70 percent. People with the C677T variant have impaired methylation capacity, which raises homocysteine, reduces nitric oxide availability, and dysregulates the pain-modulating neurotransmitter systems in the central and peripheral nervous system. The result is a nervous system that struggles to produce its own natural pain-dampening signals and accumulates homocysteine, a metabolite that itself sensitizes pain pathways.

If you carry the MTHFR C677T variant, you likely notice that your burning pain is accompanied by fatigue, difficulty concentrating, or a sense that your body is chronically under-resourced. Standard B vitamins don’t help because your body can’t process them. You may also have mildly elevated homocysteine on bloodwork, or it may be borderline and overlooked. Your pain is compounded by a cellular energy deficit and impaired synthesis of pain-regulating neurotransmitters.

VDR encodes the vitamin D receptor, the protein that allows your cells to respond to vitamin D and activate genes involved in immune regulation, calcium metabolism, and pain modulation. Vitamin D is not just a vitamin; it’s a hormone, and VDR is the key that unlocks its effects. In the nervous system, vitamin D suppresses pro-inflammatory cytokines and supports the production of nerve growth factor, which maintains healthy nerve fiber density. Low vitamin D responsiveness leaves you vulnerable to chronic inflammation and pain sensitization.

VDR variants, including the FokI polymorphism and the Bsm, Apa, and Taq variants, influence how efficiently your cells respond to vitamin D. Roughly 30 to 50% of the population carries at least one low-function variant. People with VDR variants have reduced sensitivity to vitamin D signaling, which impairs immune regulation, reduces pain-modulatory neurotrophic factors, and allows pro-inflammatory cytokines to amplify pain perception in nerve tissue. Even people with normal serum vitamin D levels can be vitamin D-resistant at the cellular level if their VDR function is compromised.

If you have a VDR variant, you likely notice that standard vitamin D supplementation doesn’t relieve your symptoms, even if your blood levels appear adequate. Your immune system may be overactive or dysregulated. You might be prone to autoimmune symptoms, allergies, or chronic inflammation. Your burning pain may be driven partly by a low-grade inflammatory state in your nervous tissue that your immune system can’t regulate because the vitamin D signaling pathway is muted.

SOD2 encodes superoxide dismutase 2, an antioxidant enzyme that sits inside mitochondria and neutralizes superoxide radicals, the toxic byproducts of cellular energy production. Mitochondria are the power plants of your cells, and SOD2 is the cleanup crew. When SOD2 function is impaired, superoxide accumulates, triggering oxidative stress, mitochondrial dysfunction, and inflammatory signaling cascades. In nerve cells, which are energy-hungry and sensitive to oxidative damage, this creates a vicious cycle: poor energy production amplifies pain sensitization.

SOD2 variants, including the Ala16Val polymorphism, are present in roughly 15 to 25% of the population and create less efficient antioxidant protection. People with SOD2 variants have impaired mitochondrial antioxidant defense, which allows oxidative stress to accumulate in nerve tissue, damaging myelin and nerve fibers and amplifying pain signaling through TRPV1 and TRPA1 pathways. The effect is magnified by lifestyle factors that increase oxidative stress: poor sleep, high-intensity exercise without adequate recovery, processed foods, and chronic stress.

If you have an SOD2 variant, you likely notice that your burning pain is worse when you’re fatigued, haven’t slept well, or have been stressed or over-exercising. Your recovery from physical activity is slow. You may have noticed that antioxidant-rich foods or supplements like NAC, alpha-lipoic acid, or CoQ10 seem to help, at least temporarily. Your nerve pain is partly a signal that your cells are energy-depleted and oxidatively stressed.

OPRM1 encodes the mu-opioid receptor, the protein on nerve cells that responds to endogenous opioids, the pain-relieving neurotransmitters your brain produces naturally during stress, exercise, or reward. These endogenous opioids, called endorphins and enkephalins, are your body’s most powerful pain-suppression system. They work by binding to OPRM1 and triggering cascades that dampen pain signal transmission. A functional OPRM1 system is essential for exercise-induced analgesia, stress-induced analgesia, and baseline pain threshold.

The A118G variant, carried by roughly 10 to 15% of people with European ancestry and up to 40% in East Asian populations, reduces mu-opioid receptor sensitivity. People with the OPRM1 A118G variant have a blunted response to endogenous opioids, which means their nervous system has a naturally lower capacity to suppress pain signals and a higher baseline pain threshold. The effect is particularly noticeable during stress or exercise; when others feel pain relief, people with the A118G variant feel little to none.

If you carry the OPRM1 A118G variant, you likely notice that exercise doesn’t give you the pain-relieving or mood-lifting effects other people report. You may not experience runner’s high or the relaxation that typically follows a good workout. Your baseline pain sensitivity is higher, and pain relief from natural endorphin release is unreliable. This doesn’t mean you can’t exercise or manage pain, but it does mean your nervous system requires other strategies to compensate for a naturally muted endogenous opioid signal.

FAAH encodes fatty acid amide hydrolase, the enzyme that breaks down anandamide, a naturally occurring endocannabinoid in your brain and nervous system. Anandamide is sometimes called the bliss molecule because it binds to cannabinoid receptors and triggers relaxation, reduces anxiety, and suppresses pain signals, particularly in the peripheral nervous system where it acts on CB1 and CB2 receptors in nerve tissue. FAAH controls how long anandamide persists in your system; lower FAAH activity means higher anandamide, more pain suppression, and a naturally higher pain threshold.

The C385A variant, present in roughly 20 to 30% of the population, reduces FAAH enzyme activity. People with the FAAH C385A variant have lower FAAH activity, which allows anandamide to accumulate, resulting in enhanced endocannabinoid signaling, lower pain sensitivity, and naturally higher pain thresholds compared to people with the common variant. The A allele appears to be protective against chronic pain conditions in population studies. However, in the context of other pain-amplifying variants, the benefit may be masked or insufficient to overcome the combined effect.

If you have the FAAH C385A variant, you may notice that cannabis or CBD products are more effective for you than for others, suggesting your endocannabinoid system is already primed for signaling. However, if you also carry variants in COMT, MTHFR, SOD2, or OPRM1, the protective effect of higher anandamide may not be enough to counteract the pain amplification from those genes. Your endocannabinoid system has good potential for pain suppression, but it may need support from other pathways.